羅傅倫博士
特聘研究員
Division Chief
- 02-2652-3079 (Lab) (Room No: N233)
- 02-2782-9142 (Fax)
-
Specialty:
- Antibody Engineering
- Directed Molecular Evolution
- Prodrugs
Education and Positions:
Ph.D. University of California, Berkeley
1. 抗體工程：建構雙特異性抗體抗體，用以遞送奈米藥物至腫瘤，改善癌症治療的選擇性與療效。
2. 奈米醫藥：正在研發新穎的技術，將疏水性藥物穩定包覆於奈米微脂體。
3. 定向分子演化：本實驗室已研發出有力的篩選方法，分選出定向演化後的優化人類酵素。我們以此技術提高蛋白質的性能，應用於治療遺傳疾病，與抗體-酵素前驅藥物療法。此外，本實驗室亦發展於抗體融合瘤細胞中，快速演化高親和力抗體的技術。
4. 前驅藥物療法：發展在腫瘤微環境內能夠優先被活化的前驅藥物，瞭解其機制以及改善活化的條件。
5. 聚乙二醇抗體：本實驗室研發聚乙二醇抗體，用以檢測人類血液檢體中聚乙二醇修飾藥物含量。我們亦延伸相關研究，探討人體中已存在，或被誘發產生的聚乙二醇抗體，是否會影響聚乙二醇修飾醫藥的療效。
Our Team
期刊 176
專書 2
期刊 176 專書 2
- Chen Bing-Mae, Chen Even, Lin Yi-Chen, Tran Trieu Thi My, Turjeman Keren, Yang Shih-Hung, Cheng Tian-Lu, Barenholz Yechezkel, Roffler Steve R. Liposomes with Low Levels of Grafted Poly(ethylene glycol) Remain Susceptible to Destabilization by Anti-Poly(ethylene glycol) Antibodies. ACS Nano epub ahead of print, NA-NA (2024-08) [JCR] [WOS]
- Tseng Yi-Han, Lin Hsuan-Pei, Lin Sung-Yao, Chen Bing-Mae, Vo Thanh Nguyet Nguyen, Yang Shih-Hung, Lin Yi-Chen, Prijovic Zeljko, Czosseck Andreas, Leu Yu-Lin, Roffler Steve R Engineering stable and non-immunogenic immunoenzymes for cancer therapy via in situ generated prodrugs. Journal of Controlled Release 369, 179-198 (2024-05) [JCR] [WOS]
- Tran Trieu TM, Roffler Steve R Interactions between nanoparticle corona proteins and the immune system. Current Opinion in Biotechnology 84, 103010 (2023-12) [JCR] [WOS]
- Chen Huei-Jen, Cheng Yi-An, Chen Yu-Tung, Li Chia-Ching, Huang Bo-Cheng, Hong Shih-Ting, Chen I.-Ju, Ho Kai-Wen, Chen Chiao-Yun, Chen Fang-Ming, Wang Jaw-Yuan, Roffler Steve R., Cheng Tian-Lu, Wu Dung-Ho Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20). Cancer Nanotechnology 14(1), 78 (2023-10) [JCR] [WOS]
- Beishenaliev Adilet, Loke Yean Leng, Goh Sook Jing, Geo Hui Nee, Mugila Malar, Misran Misni, Chung Lip Yong, Kiew Lik Voon, Roffler Steve, Teo Yin Yin Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review. Journal of Controlled Release 359, 268-286 (2023-07) [JCR] [WOS]
- Chen Wei-An, Chang Deng-Yuan, Chen Bing-Mae, Lin Yi-Chen, Barenholz Yechezekel, Roffler Steve R. Antibodies against Poly(ethylene glycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines. ACS Nano 17(6), 5757-5772 (2023-03) [JCR] [WOS]
- Bavli Yaelle, Chen Bing-Mae, Gross Guy, Hershko Alon, Turjeman Keren, Roffler Steve, Barenholz Yechezkel Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine). Journal of Controlled Release 354, 316-322 (2023-02) [JCR] [WOS]
- Lin YC, Chen BM, Tran TTM, Chang TC, Al-Qaisi TS, Roffler SR* Accelerated clearance by antibodies against methoxy PEG depends on pegylation architecture.. Journal of controlled release : official journal of the Controlled Release Society 354, 354-367 (2023-01) [JCR] [WOS]
- Burnouf PA, (Roffler SR), Wu CC, Su YC Glucuronides: From biological waste to bio-nanomedical applications.. Journal of controlled release : official journal of the Controlled Release Society 349, 765-782 (2022-09) [JCR] [WOS]
- Sahoo BK, Lin YC, Tu CF, Lin CC, Liao WJ, Li FA, Li LH, Mou KY, (Roffler SR), Wang SP, Yeh CT, Yao CY, Hou HA, Chou WC, Tien HF, Yang RB* Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia.. Haematologica 10.3324/haematol.2022.281151, x (2022-08) [JCR] [WOS]
